Cargando…
Risk of falls in postmenopausal women treated with romosozumab: Preliminary indices from a meta-analysis of randomized, controlled trials
OBJECTIVES: Falls are the well-known risk factor for osteoporotic fractures and some medications can increase the risk of falls. Therefore, the aim of our study is to evaluate the effect of romosozumab on risk of falls in postmenopausal women. METHODS: Studies were searched on PubMed, Cochrane Centr...
Autores principales: | Möckel, Luis, Bartneck, Matthias, Möckel, Christina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Osteoporosis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093685/ https://www.ncbi.nlm.nih.gov/pubmed/32226829 http://dx.doi.org/10.1016/j.afos.2020.02.003 |
Ejemplares similares
-
Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021) -
Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada
por: Goeree, Ron, et al.
Publicado: (2022) -
Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study
por: Baek, Ki-Hyun, et al.
Publicado: (2021) -
Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
por: Söreskog, E., et al.
Publicado: (2021) -
Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2021)